The multifaceted TRHC Research & Development Pillar includes contributions from numerous areas of expertise and research collaborators within the TRHC Precision Pharmacotherapy Research & Development Institute (PPRDI), Office of Translational Research and Residency Programs (OTRRP), and Office of Healthcare Analytics. The success of the Research & Development Pillar relies on an ever-evolving contemplation of work from experienced clinical pharmacists, clinical research scientists, pharmaceutical scientists, drug information specialists, data scientists, data analysts, software engineers, and software developers. These research specialists serve as subject matter experts and serve in more than 45 leadership roles in professional healthcare organizations.
Together, under the leadership of Chief Scientific Officer, Dr. Jacques Turgeon, the Research & Development Pillar consistently strives to innovate and redefine the science of medication safety to optimize medication use. The Research & Development Pillar is committed to the development of proprietary products, validation, and recognition by scientific and regulatory communities, improving patient outcomes and reducing preventable healthcare utilization and costs. To date, TRHC R&D has authored 107 original research articles, nine case reports, eight editorial pieces, eight reviews, six commentaries, three clinical trials, two clinical guidelines, two mini-reviews, two systematic reviews, one book chapter, and one white paper.
Thus far in 2021, the Research & Development Pillar has 45 active research projects, 15 peer-reviewed publications in well-renowned journals, five manuscripts accepted for publication, and three National Institute of Health research grants under review.